4.6 Article

Epigenomics and Interindividual Differences in Drug Response

期刊

CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 92, 期 6, 页码 727-736

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/clpt.2012.152

关键词

-

资金

  1. Swedish Cancer Foundation
  2. Swedish Research Council
  3. European Union
  4. Innovative Medicines Initiative

向作者/读者索取更多资源

Epigenomics is a rapidly growing field. New developments in epigenetics, such as the recently described modified cytosine variants (e.g., 5-hydroxymethylcytosine, 5hmC) and an arsenal of novel noncoding forms of RNA, can be applied in the area of drug pharmacokinetics and pharmacodynamics. Epigenetic aberrations can affect drug treatment by modulating the expressions of key genes involved in the metabolism and distribution of drugs as well as drug targets, thereby contributing to interindividual variation in drug response. These epigenetic alterations, along with the epigenetic profiles of circulating nucleic acids, have great potential to be used as biomarkers for personalized therapy, particularly in the treatment of cancer. In this review we present an update of pharmacoepigenetics with respect to epigenetic regulation of ADME genes (genes related to drug absorption, distribution, metabolism, and excretion) and drug targets, and we illustrate how this information can be used for predicting interindividual variations in drug response.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Psychiatry

Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure A Systematic Review and Meta-analysis

Filip Milosavljevic, Nikola Bukvic, Zorana Pavlovic, Cedo Miljevic, Vesna Pesic, Espen Molden, Magnus Ingelman-Sundberg, Stefan Leucht, Marin M. Jukic

Summary: This study quantified the differences in exposure to various psychiatric drugs among patients with genetically associated CYP2C19 and CYP2D6 poor, intermediate, and normal metabolism, providing a scientific foundation for genotype-based dosing recommendations that could improve clinical outcomes for patients with psychiatric disorders.

JAMA PSYCHIATRY (2021)

Review Pharmacology & Pharmacy

3D human liver spheroids for translational pharmacology and toxicology

Magnus Ingelman-Sundberg, Volker M. Lauschke

Summary: Drug development is a challenging and failure-prone process, with liver toxicity being a major cause of safety failures. The current preclinical systems for compound selection are inadequate, necessitating the development of new strategies to increase clinical success rates. Human liver spheroids are becoming increasingly utilized for various analyses and drug development, showing promise as a new standard in translational pharmacology and toxicology.

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2022)

Article Pharmacology & Pharmacy

The Polymorphic Nuclear Factor NFIB Regulates Hepatic CYP2D6 Expression and Influences Risperidone Metabolism in Psychiatric Patients

Hasan Cagin Lenk, Katharina Kloditz, Inger Johansson, Robert Lovsletten Smith, Marin Jukic, Espen Molden, Magnus Ingelman-Sundberg

Summary: This translational study evaluated the role of NFIB genetic polymorphism in the interindividual variability of the polymorphic CYP2D6 enzyme activity. The results showed that NFIB regulates CYP2D6 gene expression and its polymorphism can predict the rate of CYP2D6 dependent drug metabolism in vivo.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)

Editorial Material Pharmacology & Pharmacy

The missing heritability in pharmacogenomics: role of NFIB and other factors

Magnus Ingelman-Sundberg

Summary: Genetic variation in polymorphic genes plays a crucial role in influencing the pharmacokinetics and pharmacodynamics of different drugs through various mechanisms, contributing to the observed phenotypic variability.

PHARMACOGENOMICS (2022)

Article Cell Biology

Hepatocyte Thorns, A Novel Drug-Induced Stress Response in Human and Mouse Liver Spheroids

Chris S. Pridgeon, Dian P. Bolhuis, Filip Milosavljevic, Marina Manojlovic, Akos Vegvari, Massimiliano Gaetani, Marin M. Jukic, Magnus Ingelman-Sundberg

Summary: 3D liver spheroids provide a suitable model for studying chronic drug-induced liver toxicity and have revealed a novel drug-induced stress response. The formation of long slender filaments, known as thorns, may indicate hepatocyte metaplasia in response to toxicity, and alterations in ECM-derived protein expression could serve as biomarkers for liver disease and chronic drug-induced hepatotoxicity.
Article Pharmacology & Pharmacy

Liquid Biopsies or Therapeutic Drug Monitoring for CYP Activity Profile Determination

Chris S. Pridgeon, Inger Johansson, Magnus Ingelman-Sundberg

Summary: This study validated the use of liquid biopsy-based quantification of cfRNA in plasma exosomes as a proxy measurement for predicting hepatic CYP gene expression and drug metabolism rate, but the correlations were too weak to be a reliable substitute for therapeutic drug monitoring (TDM).

CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)

Article Genetics & Heredity

The clinically relevant CYP2C8*3 and CYP2C9*2 haplotype is inherited from Neandertals

Sigrid Haeggstrom, Magnus Ingelman-Sundberg, Svante Paabo, Hugo Zeberg

Summary: Genetic variation in genes encoding cytochrome P450 enzymes affects the metabolism of drugs and endogenous compounds. The locus on chromosome 10 containing the cytochrome genes CYP2C8 and CYP2C9 shows linkage disequilibrium between the CYP2C8*3 and CYP2C9*2 alleles, resulting in a haplotype associated with altered drug metabolism. We demonstrate that this haplotype is inherited from Neanderthals and plays a significant role in the metabolism of warfarin and phenytoin.

PHARMACOGENOMICS JOURNAL (2022)

Letter Pharmacology & Pharmacy

Response to Rowland et al. and Achour et al.

Chris S. Pridgeon, Inger Johansson, Magnus Ingelman-Sundberg

CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)

Article Medicine, Research & Experimental

Impact of NFIB and CYP1A variants on clozapine serum concentration-A retrospective naturalistic cohort study on 526 patients with known smoking habits

Hasan Cagin Lenk, Robert Lovsletten Smith, Kevin S. O'Connell, Marin M. Jukic, Marianne Kristiansen Kringen, Ole A. Andreassen, Magnus Ingelman-Sundberg, Espen Molden

Summary: This study found that genetic variants in CYP1A and NFIB have a significant impact on the dose requirements and clinical response of clozapine, especially in smokers. Smokers carrying these genetic variants may require higher doses to achieve therapeutic effects.

CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2023)

Review Pharmacology & Pharmacy

Pharmacogenomics in treatment of depression and psychosis: an update

Marin Jukic, Filip Milosavljevi, Espen Molden, Magnus Ingelman-Sundberg

Summary: Pharmacogenomic psychiatry, a well-developed research field in oncology, is expanding in psychiatry. Recent large studies have shown that preemptive genotyping can bring true benefits and cost-effectiveness to psychotherapy. However, there is still a lack of knowledge on many other heritable genetic factors that play a crucial role in explaining interindividual differences in response to psychiatric drugs. Therefore, more effort should be put into further developing pharmacogenomic psychiatry for broader clinical implementation.

TRENDS IN PHARMACOLOGICAL SCIENCES (2022)

Article Cell Biology

The Role of CTGF in Liver Fibrosis Induced in 3D Human Liver Spheroids

Sara Redensek Trampuz, Sander van Riet, Asa Nordling, Magnus Ingelman-Sundberg

Summary: Connective tissue growth factor (CTGF) plays a role in regulating extracellular matrix (ECM) production and is elevated in liver fibrosis patients. In a 3D liver co-culture spheroid model, treatment with TGF-beta 1 or free fatty acids (FFA) increased the deposition of COL1A1 and expression of CTGF. Recombinant CTGF and angiotensin II also induced the expression of CTGF, TGF-beta 1, COL1A1, LOX, and IL-6. Silencing CTGF reduced COL1A1 deposition induced by both TGF-beta 1 and FFA. IL-6 was found to induce CTGF, COL1A1, and TGF-beta 1 production, suggesting its involvement in the CTGF-induced fibrosis pathway.
Article Pharmacology & Pharmacy

Evidence for solanidine as a dietary CYP2D6 biomarker: Significant correlation with risperidone metabolism

Birgit M. Wollmann, Robert L. Smith, Marianne Kristiansen Kringen, Magnus Ingelman-Sundberg, Espen Molden, Elisabet Storset

Summary: This study aimed to investigate the correlation between solanidine metabolism and CYP2D6-mediated metabolism of risperidone in patients with known CYP2D6 genotypes. The results showed strong positive correlations between solanidine metabolism and CYP2D6-mediated risperidone metabolism.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2023)

Article Pharmacology & Pharmacy

Mechanistic, Functional, and Clinical Aspects of Pro-inflammatory Cytokine Mediated Regulation of ADME Gene Expression in 3D Human Liver Spheroids

Katharina Kloditz, Eida Tewolde, Asa Nordling, Magnus Ingelman-Sundberg

Summary: During systemic inflammation, pro-inflammatory cytokines have significant effects on the expression of genes encoding drug metabolizing enzymes. A 3D liver spheroid model was used to study these effects and found that certain cytokines decrease the expression of CYP3A4 and UGT2B10, while increasing the expression of CYP2E1 and UGT1A3. Inhibitors of JAK1/2 were able to inhibit these cytokine-induced changes. These findings suggest that the 3D spheroid system is a versatile tool for studying drug metabolism under inflammatory conditions.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2023)

Article Pharmacology & Pharmacy

3D Spheroid Primary Human Hepatocytes for Prediction of Cytochrome P450 and Drug Transporter Induction

Erkka Jarvinen, Helen S. Hammer, Oliver Poetz, Magnus Ingelman-Sundberg, Tore Bjerregaard Stage

Summary: The study assessed the usage of 3D spheroid primary human hepatocytes (PHHs) for studying the induction of important cytochrome P450 enzymes and drug transporters. The results showed that the 3D spheroid PHHs model can effectively investigate the mRNA and protein induction of hepatic drug-metabolizing enzymes and transporters, providing a solid basis for clinically relevant research.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2023)

Letter Pharmacology & Pharmacy

What is the Current Clinical Impact of the CYP2CTG Haplotype?

Magnus Ingelman-Sundberg, Marin Jukic, Line Skute Braten, Marianne Kristiansen Kringen, Espen Molden

CLINICAL PHARMACOLOGY & THERAPEUTICS (2023)

暂无数据